

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSIDE INFORMATION ANNOUNCEMENT

BIOLOGICS LICENSE APPLICATION FOR LONAPEGSOMATROPIN FOR INJECTION (TRADE NAME IN MAINLAND CHINA: 维臻高 AND THE ENGLISH TRADE NAME: SKYTROFA) APPROVED BY THE NMPA

This announcement is made by VISEN Pharmaceuticals (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the National Medical Products Administration (“**NMPA**”) of China has approved the biologics license application (“**BLA**”) for lonapegsomatropin for injection (trade name in Mainland China: 维臻高® and the English trade name: SKYTROFA®) for the treatment of pediatric and adolescent patients 3 years and older who have growth failure due to inadequate secretion of growth hormone in China.

Lonapegsomatropin is a once-weekly growth hormone replacement therapy for pediatric growth hormone deficiency (“**PGHD**”) evaluated in a completed Phase 3 pivotal trial in China, and is, to date, the only long-acting growth hormone (“**LAGH**”) with superior efficacy and comparable safety in active-controlled and parallel-group comparison to daily human growth hormone (“**hGH**”). Leveraging its novel molecular design, lonapegsomatropin is the only LAGH that releases unmodified hGH *in vivo* consistently in between weekly doses. Such unmodified human growth hormone is identical in molecular structure and mode of action to the endogenous growth hormone secreted by the pituitary gland. Its mode of action includes both the direct action between growth hormone and target tissues, and the indirect action through promoting insulin-like growth factor-1 production in the liver. In contrast, modified hGH often substantially alters the natural growth hormone molecule in terms of its molecular size, receptor binding affinity, and target tissue distribution. Lonapegsomatropin provides a convenient once-weekly dosing regimen in injection frequency as compared to once-daily hGH, which may foster increased dosing compliance for pediatric patients in daily lives.

The granting of marketing approval for this new drug is mainly based on the completed Phase 3 pivotal trial in China in children aged 3 to 17 years old with growth hormone deficiency. In this trial, lonapegsomatropin was observed with an annualized height velocity of 10.66 cm/year compared to 9.75 cm/year for daily hGH at 52 weeks, with a treatment difference of 0.91 cm/year (95% CI: 0.37-1.45, P=0.0010). Height standard deviation scores (“SDS”) at 52 weeks increased from baseline by 1.01 for lonapegsomatropin group and by 0.83 for daily hGH group, with a p-value of 0.0015, and from Week 13 onwards, the improvement in height SDS in the lonapegsomatropin group became statistically significant greater than that in the daily hGH group. The topline results of the trial have demonstrated consistency with the completed global pivotal Phase 3 trial, which supported the marketing approvals from the FDA and the EMA in PGHD and demonstrated lonapegsomatropin’s superior efficacy and comparable safety in comparison with daily hGH.

Following the BLA approval of lonapegsomatropin, the Group has launched a comprehensive commercialization plan to secure supply and expand market reach. To secure the supply of lonapegsomatropin at commercial launch, the Group has entered into commercial supply agreements with its collaboration partner, Ascendis Pharma. In parallel, the Group has strengthened its commercial capabilities by building up a focused and specialized commercialization team and implementing tailor-made programs for commercialization, physician awareness, and market access. In addition, the Group has also entered into strategic collaborations with Shanghai Pharmaceutical, United Family Healthcare and Anke Biotechnology to drive distribution and promotional activities for lonapegsomatropin.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that lonapegsomatropin for injection (trade name in Mainland China: 維臻高® and the English trade name: SKYTROFA®) will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.visenpharma.com for more information.

By order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, January 26, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Mr. LU An-Bang as executive director; (ii) Mr. FU Shan and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, Ms. NI Hong and Mr. ZHANG Qing as independent non-executive directors.